Patents by Inventor Tetsu Saito

Tetsu Saito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220148709
    Abstract: Deterioration of symptoms of a patient is prevented. A supporter terminal (3-n) contains a display unit (32) for selectably displaying pre-prepared messages effective for treatment of the patient when an event that the patient uses a patient terminal to start training for the treatment is notified through a network, and a terminal control unit (34) for displaying a message selected by a supporter for the patient from among the messages displayed on the display unit (32) on the patient terminal through the network as a message from the supporter.
    Type: Application
    Filed: April 28, 2019
    Publication date: May 12, 2022
    Applicant: LIFE QUEST Inc.
    Inventors: Ryozo SAITO, Tetsu KAYAMA, Takuma FUKUDA, Hirotsugu TAKAHASHI, Yuji GAMO, Emi ITO
  • Publication number: 20100144677
    Abstract: A convenient screening tool and a convenient screening method for obtaining an agent for treating diabetes, a pharmaceutical composition for treating diabetes, and a process for manufacturing the pharmaceutical composition are disclosed. The screening tool is a G protein-coupled receptor, a variation functionally equivalent thereto, or a homologous polypeptide thereof which promotes insulin secretion under a high glucose concentration by activation, or cells transformed with an expression vector comprising a polynucleotide encoding the above polypeptide and expressing the polypeptide.
    Type: Application
    Filed: November 19, 2009
    Publication date: June 10, 2010
    Applicant: ASTELLAS PHARMA, INC.
    Inventors: Takahide Ohishi, Jun Takasaki, Mitsuyuki Matsumoto, Tetsu Saito, Masazumi Kamohara, Takatoshi Soga, Shigeru Yoshida, Yoshitaka Ueda
  • Patent number: 7662775
    Abstract: The invention relates to a convenient screening tool for identifying an agent for treating diabetes. The screening tool is a G protein-coupled receptor, a variant of the G protein-coupled receptor, or a homolog of the G protein-coupled receptor, which promotes insulin secretion under a high glucose concentration by activation. The invention also relates to cells transformed with an expression vector comprising a polynucleotide encoding and expressing the screening tool. The invention provides a convenient screening method for identifying an agent for treating diabetes, pharmaceutical compositions comprising the agent, and a process for manufacturing the pharmaceutical composition.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: February 16, 2010
    Assignee: Astellas Pharma Inc.
    Inventors: Takahide Ohishi, Jun Takasaki, Mitsuyuki Matsumoto, Tetsu Saito, Masazumi Kamohara, Takatoshi Soga
  • Publication number: 20090215868
    Abstract: The present invention provides a prophylactic, therapeutic or ameliorative medicament for chronic obstructive pulmonary disease (COPD), cystic fibrosis or pulmonary hypertension. More specifically, the present invention provides: (1) a prophylactic, therapeutic or ameliorative medicament for chronic obstructive pulmonary disorder (COPD), cystic fibrosis or pulmonary hypertension, having an NF-?B decoy as the active ingredient thereof; (2) the NF-?B decoy is an oligonucleotide containing the binding sequence GGGRHTYYC (where R represents either A or G; Y represents either C or T; and H represents either A, C or T); (3) an oligonucleotide wherein the NF-?B binding sequence is GGGATTTCCC or GGGACTTTCC; (4) an oligonucleotide wherein the NF-?B decoy is represented by SEQ ID NO:3; (5) the NF-?B decoy is a double-stranded oligonucleotide; (6) the NF-?B decoy is administered in the form of a fine powder; and (7) the NF-?B decoy fine powder is a dry powder.
    Type: Application
    Filed: January 12, 2006
    Publication date: August 27, 2009
    Applicant: ANGES MG, INC.
    Inventors: Kunimiki Otsu, Tetsu Saito, Takefumi Gemba
  • Patent number: 7405051
    Abstract: A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2TAC protein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2TAC ligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: July 29, 2008
    Assignee: Astellas Pharma Inc.
    Inventors: Jun Takasaki, Mitsuyuki Matsumoto, Masazumi Kamohara, Tetsu Saito, Takahide Ohishi, Takatoshi Soga
  • Patent number: 7341849
    Abstract: This invention belongs to the genetic engineering field, and provides novel G protein-coupled receptor family proteins SREB1, SREB2 and SREB3 expressed in the central nervous system, genes coding for these proteins, screening methods using these proteins and so on. As one of the methods for obtaining the G protein-coupled receptor proteins of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: March 11, 2008
    Assignee: Astellas Pharma Inc.
    Inventors: Mitsuyuki Matsumoto, Toru Sugimoto, Jun Takasaki, Masazumi Kamohara, Tetsu Saito, Masato Kobayashi
  • Patent number: 7217800
    Abstract: A cDNA encoding a novel LTC4 receptor has been isolated. Provision of the novel protein, an LTC4 receptor, enabled binding experiments using the LTC4. By screening for compounds that modulate LTC4 receptor activity based on these binding experiments, development of drugs targeting the LTC4 receptor becomes possible.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: May 15, 2007
    Assignees: Astellas Pharma Inc., Helix Research Institute
    Inventors: Jun Takasaki, Masazumi Kamohara, Mitsuyuki Matsumoto, Tetsu Saito, Tohru Sugimoto, Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Yuri Kawai
  • Publication number: 20050159355
    Abstract: This invention provides a nucleic acid encoding a novel leukotriene B4 receptor, a vector containing this nucleic acid, a method for screening a substance capable of modifying the activity of the receptor by using a host cell containing the vector and the receptor, and pharmaceutical compositions for inflammatory diseases containing as the active ingredient a substance capable of modifying the activity of the receptor.
    Type: Application
    Filed: December 16, 2004
    Publication date: July 21, 2005
    Inventors: Masazumi Kamohara, Mitsuyuki Matsumoto, Jun Takasaki, Tetsu Saito, Takahide Ohishi
  • Publication number: 20050136484
    Abstract: A convenient screening tool and a convenient screening method for obtaining an agent for treating diabetes, a pharmaceutical composition for treating diabetes, and a process for manufacturing the pharmaceutical composition are disclosed. The screening tool is a G protein-coupled receptor, a variation functionally equivalent thereto, or a homologous polypeptide thereof which promotes insulin secretion under a high glucose concentration by activation, or cells transformed with an expression vector comprising a polynucleotide encoding the above polypeptide and expressing the polypeptide.
    Type: Application
    Filed: October 29, 2004
    Publication date: June 23, 2005
    Inventors: Takahide Ohishi, Jun Takasaki, Mitsuyuki Matsumoto, Tetsu Saito, Masazumi Kamohara, Takatoshi Soga, Shigeru Yoshida, Yoshitaka Ueda
  • Patent number: 6878525
    Abstract: A cDNA encoding a novel LTC4 receptor has been isolated. Provision of the novel protein, an LTC4 receptor, enabled binding experiments using the LTC4. By screening for compounds that modulate LTC4 receptor activity based on these binding experiments, development of drugs targeting the LTC4 receptor becomes possible.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: April 12, 2005
    Assignees: Yamanouchi Pharmaceutical Co, Ltd., Helix Research Institute
    Inventors: Jun Takasaki, Masazumi Kamohara, Mitsuyuki Matsumoto, Tetsu Saito, Tohru Sugimoto, Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Yuri Kawai
  • Publication number: 20050042683
    Abstract: This invention belongs to the genetic engineering field, and provides novel G protein-coupled receptor family proteins SREB1, SREB2 and SREB3 expressed in the central nervous system, genes coding for these proteins, screening methods using these proteins and so on. As one of the methods for obtaining the G protein-coupled receptor proteins of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.
    Type: Application
    Filed: July 26, 2004
    Publication date: February 24, 2005
    Inventors: Mitsuyuki Matsumoto, Toru Sugimoto, Jun Takasaki, Masazumi Kamohara, Tetsu Saito, Masato Kobayashi
  • Publication number: 20050037968
    Abstract: A cDNA encoding a novel LTC4 receptor has been isolated. Provision of the novel protein, an LTC4 receptor, enabled binding experiments using the LTC4. By screening for compounds that modulate LTC4 receptor activity based on these binding experiments, development of drugs targeting the LTC4 receptor becomes possible.
    Type: Application
    Filed: September 2, 2004
    Publication date: February 17, 2005
    Inventors: Jun Takasaki, Masazumi Kamohara, Mitsuyuki Matsumoto, Tetsu Saito, Tohru Sugimoto, Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Yuri Kawai
  • Publication number: 20040241757
    Abstract: An endogenous receptor for human prokineticins 1 and 2, which do not affect gastrointestinal system contractive action and spermatogenesis action but exert influences upon central nervous system actions, particularly neuronal death inhibitory action, was identified. There is disclosed a method for conveniently screening a useful substance which can control central nervous system actions, for example, a substance useful as an agent for treating dementia and stroke known as neuronal death-accompanying diseases and/or hyperalgesia, by using the aforementioned receptor and/or a cell transformed with the aforementioned receptor.
    Type: Application
    Filed: March 19, 2004
    Publication date: December 2, 2004
    Inventors: Shunichiro Matsumoto, Jun Takasaki, Tetsu Saito, Takatoshi Soga, Masazumi Kamohara, Hideki Hiyama
  • Patent number: 6808899
    Abstract: This invention belongs to the genetic engineering field, and provides novel G protein-coupled receptor family proteins SREB1, SREB2 and SREB3 expressed in the central nervous system, genes coding for these proteins, screening methods using these proteins and so on. As one of the methods for obtaining the G protein-coupled receptor proteins of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: October 26, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Mitsuyuki Matsumoto, Toru Sugimoto, Jun Takasaki, Masazumi Kamohara, Tetsu Saito, Masato Kobayashi
  • Publication number: 20030180813
    Abstract: A convenient screening tool and a convenient screening method for obtaining an agent for treating diabetes, a pharmaceutical composition for treating diabetes, and a process for manufacturing the pharmaceutical composition are disclosed.
    Type: Application
    Filed: October 2, 2002
    Publication date: September 25, 2003
    Inventors: Takahide Ohishi, Jun Takasaki, Mitsuyuki Matsumoto, Tetsu Saito, Masazumi Kamohara, Takatoshi Soga, Shigeru Yoshida, Yoshitaka Ueda
  • Publication number: 20030124626
    Abstract: A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2TAC protein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2TAC ligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.
    Type: Application
    Filed: January 24, 2003
    Publication date: July 3, 2003
    Inventors: Jun Takasaki, Mitsuyuki Matsumoto, Masazumi Kamohara, Tetsu Saito, Takahide Ohishi, Takatoshi Soga
  • Patent number: 6555344
    Abstract: This invention belongs to the genetic engineering field, and provides the novel G protein-coupled receptor family protein SREB2 expressed in the central nervous system, genes coding for the protein, screening methods using the protein and so on. As one of the methods for obtaining the G protein-coupled receptor protein of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: April 29, 2003
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Mitsuyuki Matsumoto, Toru Sugimoto, Jun Takasaki, Masazumi Kamohara, Tetsu Saito, Masato Kobayashi
  • Publication number: 20030077709
    Abstract: This invention provides a nucleic acid encoding a novel leukotriene B4 receptor, a vector containing this nucleic acid, a method for screening a substance capable of modifying the activity of the receptor by using a host cell containing the vector and the receptor, and pharmaceutical compositions for inflammatory diseases containing as the active ingredient a substance capable of modifying the activity of the receptor.
    Type: Application
    Filed: April 29, 2002
    Publication date: April 24, 2003
    Inventors: Masazumi Kamohara, Mitsuyuki Matsumoto, Jun Takasaki, Tetsu Saito, Takahide Ohishi
  • Publication number: 20030077662
    Abstract: This invention belongs to the genetic engineering field, and provides novel G protein-coupled receptor family proteins SREB1, SREB2 and SREB3 expressed in the central nervous system, genes coding for these proteins, screening methods using these proteins and so on.
    Type: Application
    Filed: December 13, 2002
    Publication date: April 24, 2003
    Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuyuki Matsumoto, Toru Sugimoto, Jun Takasaki, Masazumi Kamohara, Tetsu Saito, Masato Kobayashi
  • Patent number: 5965725
    Abstract: The present invention relates to polypeptide having a primary structure of amino acid sequence shown by Sequence List Sequence No. 1 and DNA encoding for the polypeptide. The polypeptide is obtainable by following steps (1)-(3):Step (1): extracting small granule fraction of homocytes of horseshoe crab with a buffer containing protein denaturing agent and chelating agent,Step (2): subjecting said extract to reverse phase high performance liquid chromatography,Step (3): eluting by concentration gradient elution with a hydrophobic organic solvent.Also, the polypeptide is produced by chemical synthesis. The polypeptide has similar chemical structure to defensin and is useful as gargles, disinfectants, antiseptics or antimicrobials.
    Type: Grant
    Filed: February 3, 1998
    Date of Patent: October 12, 1999
    Assignee: Seikagaku Kogyo Kabushiki Kaisha
    Inventors: Sadaaki Iwanaga, Shun-ichiro Kawabata, Tetsu Saito